Hanmi Pharmaceutical Earnings Beat Expectations – What Drives the Rally? Hanmi Pharmaceutical is rated Buy: revenue +29.3% YoY, gross margin 59.6%, net income +115.2% YoY, but operating profit -36.0% YoY and China receivables governance risk remain. Valuation below average target. 2026년 09월 21일 English
IBK Industrial Bank Holds Valuation but Faces Governance Risk IBK Industrial Bank rated Hold as cheap valuation is offset by China loan fraud and governance risk, causing profit decline and possible higher compliance costs. 2026년 08월 26일 English
